The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Treatment of Richter’s transformation: recent insights
Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, comments on recent insights into the treatment of patients with Richter’s transformation (RT), where an aggressive lymphoma develops in a patient with chronic lymphocytic leukemia (CLL). Dr Al-Sawaf discusses trials investigating glofitamab (NCT03075696), as well as venetoclax in combination with atezolizumab and obinutuzumab (EUDRACT 2018-005028-40) for RT, highlighting the improved efficacy observed compared to standard chemotherapy. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
